[go: up one dir, main page]

TW200719914A - Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers - Google Patents

Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers

Info

Publication number
TW200719914A
TW200719914A TW095113028A TW95113028A TW200719914A TW 200719914 A TW200719914 A TW 200719914A TW 095113028 A TW095113028 A TW 095113028A TW 95113028 A TW95113028 A TW 95113028A TW 200719914 A TW200719914 A TW 200719914A
Authority
TW
Taiwan
Prior art keywords
genitourinary
lymphoid
gastrointestinal
treatment
growth factor
Prior art date
Application number
TW095113028A
Other languages
English (en)
Chinese (zh)
Inventor
William Berg
David Lebwohl
Andrea Kay
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200719914A publication Critical patent/TW200719914A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095113028A 2005-04-13 2006-04-12 Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers TW200719914A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67087005P 2005-04-13 2005-04-13
US68039605P 2005-05-12 2005-05-12

Publications (1)

Publication Number Publication Date
TW200719914A true TW200719914A (en) 2007-06-01

Family

ID=36649704

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095113028A TW200719914A (en) 2005-04-13 2006-04-12 Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers

Country Status (6)

Country Link
AR (1) AR053576A1 (fr)
GT (1) GT200600147A (fr)
PE (1) PE20061361A1 (fr)
TW (1) TW200719914A (fr)
UY (1) UY29471A1 (fr)
WO (1) WO2006113172A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion

Also Published As

Publication number Publication date
AR053576A1 (es) 2007-05-09
WO2006113172A1 (fr) 2006-10-26
GT200600147A (es) 2006-11-24
UY29471A1 (es) 2006-11-30
PE20061361A1 (es) 2007-01-03

Similar Documents

Publication Publication Date Title
UA99833C2 (en) Pyrimidinyl pyridazinone derivates
MX2009008222A (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
GEP20125664B (en) Condensed heterocyclic derivatives and application thereof
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
IL186104A0 (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
TN2010000236A1 (en) Fused pyridine pyrimidine and triazine compounds as cell cycle inhibitors
MX355632B (es) Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres.
TW200833662A (en) 4,5-ring annulated indole derivatives and methods of use thereof
JO3134B1 (ar) مثبطات نشاط akt
HRP20080377A2 (en) ACTIVIN ActRIIa ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH
MX2009008698A (es) Arabinoxilo-oligosacaridos en cerveza.
WO2008015383A3 (fr) Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer
MY173616A (en) Compositions and methods for lowering triglycerides
MXPA05011353A (es) Compuestos heterociclicos que se unen al receptor de quimiocina con eficacia mejorada.
PL2173337T3 (pl) Fosfaplatyny i ich zastosowanie w leczeniu raków opornych na cisplatynę i karboplatynę
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
SG171583A1 (en) Composition for the treatment of resistant cancers comprising oridonin
MX2009001516A (es) Aplicacion por via transdermica de triazinas para combatir infecciones por coccidios.
MX2011007165A (es) Derivados de piridazinona.
IL196825A0 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers
MX2009004436A (es) Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3.
WO2008033887A8 (fr) Procédés de traitement du cancer
MX2010004259A (es) Tratamientos antitumorales mejorados.
TW200719914A (en) Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers